MedDataX Logo

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

NCT ID: NCT00097344

Last Updated: 2007-08-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

842 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-12-31

Study Completion Date

2006-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying the growth of breast cancer, and whether the side effects of the combined hormonal therapy are different from the side effects of letrozole.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aromatase is an enzyme expressed in tissues such as muscle and fat in postmenopausal women. These non-ovarian tissues become the dominant sources of estrogen in postmenopausal women. Breast cancer cells are often very dependent on estrogens to continue to grow. Atamestane blocks the formation of estrogens from androgenic precursors in the body via the aromatase enzyme. Toremifene blocks circulating and intracellular estrogens from stimulating estrogen receptors in breast cancer cells. The goal of therapy with atamestane, an aromatase inhibitor, in combination with the estrogen receptor antagonist, toremifene, is to achieve complete suppression of estrogen stimulation of breast cancer cells. This study is designed to determine whether combined hormonal therapy will lengthen the time to disease progression and the rate of objective response, as compared to single agent therapy with the approved aromatase inhibitor letrozole.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Neoplasms Neoplasms, Hormone-Dependent

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atamestane

Intervention Type DRUG

Toremifene

Intervention Type DRUG

Letrozole

Intervention Type DRUG

Aromatase inhibition

Intervention Type DRUG

Estrogen receptor blocker

Intervention Type DRUG

Hormone therapy

Intervention Type PROCEDURE

Endocrine therapy

Intervention Type PROCEDURE

Antiestrogen therapy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women age 18 years or older
* Postmenopausal women who are to receive their first hormonal treatment for locally recurrent, locally advanced, or metastatic disease, and who would be appropriate candidates for treatment with antiestrogens or aromatase inhibitors.
* Locally recurrent, locally advanced, locally metastatic disease not amenable to radiation therapy or surgery and/or distant metastatic disease.
* Pathological or histological confirmation at primary diagnosis of breast cancer or at the time of diagnosis of advanced disease.
* ECOG performance status of 0, 1 or 2 or Karnofsky performance status of 60 or higher.
* Predicted life expectancy of 12 weeks or more.
* Postmenopausal endocrine status. LH/FSH levels in the postmenopausal range in women whose menopause occurred less than 5 years ago.
* At least one tumor localization measurable in 2 dimensions.

* One diameter either at least 2 cm or at least two times the CT/MRI slice/reconstruction thickness for bone/soft tissue/visceral disease assessed by CT/MRI scan (to include spiral CT technique).
* One diameter at least 2 cm for lesions other than bone lesions assessed by conventional X-ray techniques.
* One diameter at least 1 cm for bone lesions assessed by conventional X-ray techniques.
* Estrogen receptor and/or progesterone receptor positive (by laboratory/institutional standard) at the time of primary diagnosis or determined during subsequent biopsy/surgery of metastases.
* Administration of bisphosphonates in patients with bone metastases is allowed, as long as the drug is started prior to randomization of the patient.
* Written informed consent obtained.

Exclusion Criteria

* Prior hormonal therapy (including oophorectomy or treatment with LH/RH analogs) to treat locally recurrent, locally advanced, or metastatic disease.
* Prior chemotherapy to treat locally recurrent, locally advanced, or metastatic disease.
* Prior adjuvant therapy with aromatase inhibitors or antiestrogens/SERMs with last dose administered within 3 months prior to enrollment.
* Primary diagnosis of disease or progression of disease during therapy with antiestrogens (including SERMs administered for prevention of osteoporosis).
* Life-threatening disease requiring chemotherapeutic intervention.
* History of known CNS metastases, significant neurological dysfunction including active seizures, or clinical signs of other significant neurological diseases.
* Other active malignancy (except basal cell carcinoma of the skin, contralateral breast cancer, or in situ cervical cancer). Patients with previous malignancies must be without evidence of disease for at least five years.
* Renal insufficiency (serum creatinine \>2.0 mg/dL).
* Aspartate aminotransferase, alanine aminotransferase, or serum bilirubin levels more than 2.5 times upper limit of normal.
* Hemoglobin \<9 g/dL.
* Platelet count of less than 100,000 platelets per mm3.
* Total white blood cell count of less than 2,000 cells per mm3.
* Premenopausal endocrine status; pregnant or lactating females.
* Usage of an investigational drug within thirty (30) days prior to enrollment; or the planned usage of an investigational drug other than the study medication during the course of the current study.
* Contraindication to use of toremifene, atamestane, letrozole, or any of the inactive components of their formulations as stated in the investigators brochure or product package insert.
* Patients who are unable to comply with the study requirements or diagnostic procedures.
* Prior enrollment in this study.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Intarcia Therapeutics

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Edith Perez, MD

Role: STUDY_CHAIR

Professor of Medicine, Mayo Clinic, Jacksonville, Florida

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Mobile, Alabama, United States

Site Status

Research Site

Tuscon, Arizona, United States

Site Status

Research Site

Hot Springs, Arkansas, United States

Site Status

Research Site

Fountain Valley, California, United States

Site Status

Research Site

Greenbrae, California, United States

Site Status

Research Site

Los Angeles, California, United States

Site Status

Research Site

Poway, California, United States

Site Status

Research Site

Greenwich, Connecticut, United States

Site Status

Research Site

Jacksonville, Florida, United States

Site Status

Research Site

Kissimmee, Florida, United States

Site Status

Research Site

Miami, Florida, United States

Site Status

Research Site

Ocala, Florida, United States

Site Status

Research Site

Pembroke Pines, Florida, United States

Site Status

Research Site

Tampa, Florida, United States

Site Status

Research Site

Augusta, Georgia, United States

Site Status

Research Site

Savannah, Georgia, United States

Site Status

Research Site

Evansville, Indiana, United States

Site Status

Research Site

New Albany, Indiana, United States

Site Status

Research Site

Lenexa, Kansas, United States

Site Status

Research Site

Louisville, Kentucky, United States

Site Status

Research Site

Shreveport, Louisiana, United States

Site Status

Research Site

Towson, Maryland, United States

Site Status

Research Site

Detroit, Michigan, United States

Site Status

Research Site

Flint, Michigan, United States

Site Status

Research Site

Robbinsdale, Minnesota, United States

Site Status

Research Site

St Louis, Missouri, United States

Site Status

Research Site

Billings, Montana, United States

Site Status

Research Site

Reno, Nevada, United States

Site Status

Research Site

Cherry Hill, New Jersey, United States

Site Status

Research Site

Newark, New Jersey, United States

Site Status

Research Site

Fresh Meadows, New York, United States

Site Status

Research Site

Valhalla, New York, United States

Site Status

Research Site

Wooster, Ohio, United States

Site Status

Research Site

Zanesville, Ohio, United States

Site Status

Research Site

Philadelphia, Pennsylvania, United States

Site Status

Research Site

West Reading, Pennsylvania, United States

Site Status

Research Site

Columbia, South Carolina, United States

Site Status

Research Site

Bristol, Tennessee, United States

Site Status

Research Site

Memphis, Tennessee, United States

Site Status

Research Site

Houston, Texas, United States

Site Status

Research Site

Pasadena, Texas, United States

Site Status

Research Site

Ogden, Utah, United States

Site Status

Research Site

Chesapeake, Virginia, United States

Site Status

Research Site

Danville, Virginia, United States

Site Status

Research Site

Norfolk, Virginia, United States

Site Status

Research Site

Lacey, Washington, United States

Site Status

Research Site

Milwaukee, Wisconsin, United States

Site Status

Research Site

Racine, Wisconsin, United States

Site Status

Research Site

Rhinelander, Wisconsin, United States

Site Status

Research Site

Blagoevgrad, , Bulgaria

Site Status

Research Site

Plovdiv, , Bulgaria

Site Status

Research Site

Shumen, , Bulgaria

Site Status

Research Site

Sofia, , Bulgaria

Site Status

Research Site

Sofia, , Bulgaria

Site Status

Research Site

Stara Zagora, , Bulgaria

Site Status

Research Site

Varna, , Bulgaria

Site Status

Research Site

Arad, , Romania

Site Status

Research Site

Brasov, , Romania

Site Status

Research Site

Bucharest, , Romania

Site Status

Research Site

Bucharest, , Romania

Site Status

Research Site

Cluj-Napoca, , Romania

Site Status

Research Site

Oradea, , Romania

Site Status

Research Site

Ploieşti, , Romania

Site Status

Research Site

Târgu Mureş, , Romania

Site Status

Research Site

Timișoara, , Romania

Site Status

Research Site

Arkhanglsk, , Russia

Site Status

Research Site

Astrakhan, , Russia

Site Status

Research Site

Chelyabinsk, , Russia

Site Status

Research Site

Engel's, , Russia

Site Status

Research Site

Irkutsk, , Russia

Site Status

Research Site

Kaliningrad, , Russia

Site Status

Research Site

Kaluga, , Russia

Site Status

Research Site

Kazan', , Russia

Site Status

Research site

Krasnodar, , Russia

Site Status

Research Site

Moscow, , Russia

Site Status

Research Site

Moscow, , Russia

Site Status

Research Site

Omsk, , Russia

Site Status

Research Site

Orenburg, , Russia

Site Status

Research Site

Oryol, , Russia

Site Status

Research Site

Perm, , Russia

Site Status

Research Site

Pyatigorsk, , Russia

Site Status

Research Site

Saint Petersburg, , Russia

Site Status

Research Site

Saint Petersburg, , Russia

Site Status

Research Site

Saint Petersburg, , Russia

Site Status

Research Site

Sochi, , Russia

Site Status

Research Site

Syktyvkar, , Russia

Site Status

Research Site

Tambov, , Russia

Site Status

Research Site

Ufa, , Russia

Site Status

Research Site

Ulyanovsk, , Russia

Site Status

Research Site

Yaroslavl, , Russia

Site Status

Research Site

Chernihiv, , Ukraine

Site Status

Research Site

Chernivtsy, , Ukraine

Site Status

Research Site

Donetsk, , Ukraine

Site Status

Research Site

Kharkiv, , Ukraine

Site Status

Research Site

Kherson, , Ukraine

Site Status

Research Site

Khmelnitsky, , Ukraine

Site Status

Research Site

Luhansk, , Ukraine

Site Status

Research Site

Lutsk, , Ukraine

Site Status

Research Site

Lviv, , Ukraine

Site Status

Research Site

Mariupol, , Ukraine

Site Status

Research Site

Odesa, , Ukraine

Site Status

Research Site

Sumy, , Ukraine

Site Status

Research Site

Ternopil, , Ukraine

Site Status

Research Site

Vinnitsa, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Bulgaria Romania Russia Ukraine

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Biomed 777-CLP-30

Identifier Type: -

Identifier Source: org_study_id